ESTRO 2024 - Abstract Book

S2534

Clinical - Urology

ESTRO 2024

Tumour Stage

T1

49 (28.7)

T2

47 (27.5)

T3

67 (39.2)

T4

08 (4.7)

Gleason Grade Group

1

7 (4.1)

2

20 (11.7)

3

31 (18.1)

4

60 (35.1)

5

53 (31.0)

Prostate Radiotherapy

35Gy/5#

35 (20.5)

36.25Gy/5#

48 (28.1)

40Gy/5#

88 (51.5)

ADT duration (months)

Median, IQR

17.5 (9-24)

Figure 1. Patterns of recurrence (n=19)

Conclusion:

For patients with high-risk prostate cancer treated with SBRT, a dose of 25Gy in five fractions appears to be adequate for prophylactic pelvic nodal irradiation.